NCT03697876View on ClinicalTrials.gov

Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

June 26, 2024

Study Completion Date

June 26, 2024

Conditions
Dry Eye Syndromes
Interventions
DRUG

PRO-165

PRO-165 Chondroitin sulfate 0.18% / sodium hyaluronate 0.2%, ophthalmic gel. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.

DRUG

Artelac

Artelac® Nightime Gel. 0.2% Carbomer, ophthalmic gel. Made in Germany by: Dr. Gerhard Mann Chem Pharm. Imported and marketed by: Bausch \& Lomb México, S.A. de C.V.

Trial Locations (1)

07020

Leslie victoria Aguilar Saldaña, Mexico City

All Listed Sponsors
lead

Laboratorios Sophia S.A de C.V.

INDUSTRY

NCT03697876 - Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel | Biotech Hunter | Biotech Hunter